中药组方联合紫杉醇与卡铂治疗晚期卵巢癌的疗效及对肿瘤标记物的影响

Efficacy and Tumor-associated Markers Analysis of Chinese Medicine Combined with Paclitaxel and Carboplatin in the Treatment of Advanced Ovarian Cancer

[目的]探讨中药联合紫杉醇与卡铂治疗晚期卵巢癌的疗效以及对肿瘤相关标记物的影响。[方法]本院收治的80例晚期卵巢癌患者随机分为对照组和观察组。对照组采用紫杉醇与卡铂治疗,观察组在对照组的基础上自拟中药治疗。比较两组临床疗效,血清CA125、CA199,人附睾蛋白4(HE4)的变化以及对患者免疫功能的影响,并记录两组患者的并发症发生情况。[结果]观察组治疗有效率明显高于对照组(92.50%vs 75.00%)(P<0.05);治疗前两组CA125.CA199、HE4等指标水平相比较差异无显著性(P>0.05);治疗后观察组CA125、CA199.HE4水平明显优于对照组(P<0.05);两组患者化疗后CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)水平均较化疗前变差(P<0.05);但化疗后观察组CD3^(+),CD4^(+),CD8^(+).CD4^(+)/CD8^(+)水平优于对照组(P<0.05);观察组不良反应发生率明显低于对照组(30.00%vs 57.50%)(P<0.05)。[结论]采用中西医结合的方式治疗晚期卵巢癌患者,可有效提高临床疗效、改善患者的免疫功能,最终改善患者的预后。

[Objective]To explore the efficacy of Chinese medicine combined with paclitaxel and carboplatin in the treatment of advanced ovarian cancer and its effect on tumor associated markers.[Methods]A total of 80 patients with advanced ovarian cancer in our hospital were randomly divided into control group and observation group.The control group was treated with paclitaxel and carboplatin while the observation group was treated with traditional Chinese medicine on the basis of the same chemotherapy as the control group.The clinical efficacy,serum CA125,CA199,human epididymis protein 4(HE4)and the effect on immune function of the two groups were compared.The complications of the two groups were recorded.[Results]The elinical efficacy of the observation group was significantly higher than that of the control group(92.50%vs 75.00%)(P<0.05);There was no significant difference in the levels of CA125,CA199 and HE4 between the two groups before treatment(P>0.05).After treatment,the levels of CA125,CA199 and HE4 in the observation group were significantly better than those in the control group(P<0.05).After chemotherapy,the levels of CD3^(+),CD4,CD8^(+),CD4^(+)/CD8^(+)in both groups were worse than before chemotherapy(P<0.05),but after chemotherapy,the levels of CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)in the observation group were better than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the con-trol group(30.00%vs 57.50%)(P<0.05).[Conclusion]The combination of traditional Chinese and Western medicine in the treatment of patients with advanced ovarian cancer can effectively improve the clinical efficacy,improve the immune function of patients,and ultimately improve the prognosis of patients.